Sartorius Stedim stock gains on Barclays target hike to 240 euros
Published on 09/09/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius Stedim Biotech SA stock (ISIN FR0013154002) moved higher in recent trading after Barclays lifted its price target from 210 to 240 euros on September 8, 2026 while reiterating an Overweight rating, with the shares closing that day at 186.30 euros on Euronext Paris.
Barclays raises target and reiterates Overweight
According to finanzen.ch, Barclays Capital increased its price target for Sartorius Stedim Biotech from 210.00 euros to 240.00 euros and confirmed an Overweight recommendation in an update dated September 8, 2026.
In the same analyst overview, the stock was cited with a reference price of 186.50 euros and a distance to the new 240.00 euro target of 28.69 percent, while the current price of 189.50 euros implied a 26.65 percent upside to the target as of the latest snapshot.finanzen.ch
Stock trades below yearly high despite recent gain
A recent trading commentary from ad-hoc-news reports that Sartorius Stedim Biotech shares closed on Euronext Paris at 186.30 euros on September 8, 2026, up 1.6 percent from the prior close of 183.30 euros.
On that trading day, the stock traded between an intraday low of 186.30 euros and a high of 189.30 euros, with the closing price near the lower end of the session range.ad-hoc-news
The same overview cites a 52-week range for Sartorius Stedim Biotech shares between approximately 150.90 euros and 223.30 euros, meaning the September 8, 2026 close of 186.30 euros stood clearly below the 52-week high and roughly 23.3 percent under that yearly peak.ad-hoc-news
Stock level and valuation context for investors
Per the price figures reported by finanzen.ch, Sartorius Stedim Biotech stock was recently quoted at 189.50 euros on Euronext Paris, representing a modest daily decline of 0.26 percent compared with the immediately preceding price level.
Taking the September 8, 2026 closing price of 186.30 euros and the 52-week high of 223.30 euros from the trading commentary, the shares are trading in the lower half of their one-year range, which underpins the upside potential implied by Barclays' 240.00 euro target.ad-hoc-news
The analyst upgrade comes against a backdrop of broader coverage of the Sartorius group, where a separate Barclays note on the German-listed Sartorius preference shares also maintained an Overweight stance, signaling the bank's continued positive view on the bioprocessing specialist within the European medtech and life sciences equipment sector.finanzen.at
Sartorius Stedim stock price snapshot
As of September 8, 2026, the reference closing price for Sartorius Stedim Biotech stock on its primary exchange Euronext Paris was 186.30 euros, with the shares trading in a 52-week band between 150.90 euros and 223.30 euros.
Key data on Sartorius Stedim Biotech stock
- Company: Sartorius Stedim Biotech SA
- ISIN: FR0013154002
- Ticker: DIM
- Trading venue: Euronext Paris
- Price (as of September 8, 2026): 186.30 EUR
- Market capitalization: [value] [currency] (as of [date])
- Sector / Industry: Health Care Equipment and Services
- Index membership: [index]
